Authors: M. Dybiec, N.E. Korsunska, P. Zhukov, S. Ostapenko, T. Sellers, A. Zajac and T. Zhukov
Affilation: University of South Florida, United States
Pages: 35 - 38
Keywords: quantum dots, labeling, ovarian cancer
Ovarian cancer is the most lethal gynecologic malignancy. This largely reflects the fact that approximately 75% of cases are detected at advanced stages of disease, when cure is unlikely. In contrast, 5-year survival for patients with early stage ovarian cancer can exceed 90%. It is possible therefore that detecting a greater number of patients with early stage disease by improving screening modalities could significantly improve overall survival. To date, detection of the secreted tumor marker CA 125 is the only biomarker available for screening and therapeutic monitoring, however it has limited sensitivity (70%). A novel approach to increase the sensitivity and specificity of early detection of cancer is through the application of nanotechnology, where luminescent semiconductor quantum dots (QDs) are conjugated with biomolecules.